Clearmind Medicine

Clearmind Medicine

Clearmind Medicine operates as a clinical-stage biotech company headquartered in Canada, publicly listed on the Nasdaq under the symbol CMND. Led by CEO Adi Zuloff-Shani, the firm forms part of a small cohort of publicly traded companies that emerged during the post-2020 wave of psychedelic medicine ventures. Its core intellectual property centers on MEAI (5-methoxy-2-aminoindane), a novel psychoactive compound the company has positioned as a potential treatment for alcohol use disorder, binge eating, and related addictive behaviors. The firm's strategy relies on a pharmaceutical development model: patent-protected, pre-clinical molecule advancement through regulatory pathways. Clearmind holds a portfolio of patents across jurisdictions including the United States, Europe, and China, covering composition-of-matter and methods of use for its lead compound. The company has conducted proof-of-concept studies and pre-clinical trials in collaboration with academic institutions in Israel, targeting endpoints around alcohol consumption reduction. It does not operate as an investment vehicle or fund, but rather as an operating company burning capital to generate clinical data. As of mid-2024, Clearmind maintained a lean corporate footprint with no disclosed large-scale institutional pharmaceutical partner. The firm has pursued equity-based financing rounds typical of pre-revenue biotechs, filing prospectus supplements for at-the-market offerings to fund ongoing research. Professional headcount remains undisclosed, and the company has not reported material revenue. Its pipeline depth spans multiple indications for the same molecule, a classic biotech risk-concentration posture. The structural differentiator for Clearmind is its status as one of very few publicly traded companies controlling the IP for a single, novel psychedelic-adjacent molecule while remaining at the pre-clinical stage. Unlike larger psychedelic players such as Compass Pathways or Atai Life Sciences, which pursue multiple compounds or clinic-based therapy models, Clearmind's bet is binary: it succeeds or fails on MEAI.